Sungjong Lee, MD, PhD, The Catholic University of Korea and Seoul St. Mary’s Hospital, Seoul, Republic of Korea, provides an overview of a Phase II trial (NCT03444376) investigating pembrolizumab plus GX-188E, a therapeutic HPV DNA vaccine that encodes HPV-16 and HPV-18 E6 and E, in patients with recurrent or advanced cervical cancer who had progressed on the standard of care. The primary endpoint was objective response rate (ORR) GX-188E was observed to increase the absolute number of antigen-specific T-cells in circulation and enhanced tumor infiltration. An ORR of 32% was observed, with 10% of patients achieving complete remission (CR) and 22% achieving a partial response (PR), with an acceptable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
